----
Current ValuationThe current P/E ratio is -0.20, within the reasonable range, cheaper than 49.88% of the time in the past 5 years, and the industry ranks 30/74, the industry Median --.
-0.199xP/E
$0.00Stock price
$-0.00Earnings per share
-0.199xP/E
Stock price$0.00Earnings per share$-0.00
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.24x
- Typical range
- -0.34x–-0.20x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
07142128
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
GHUSGuardant Health | -50.04x | 3.12% | $22.69B |
HIMSUSHims & Hers Health | -45.52x | 209.86% | $6.47B |
RDNTUSRadnet | -262.15x | 128.00% | $5.54B |
NEOUSNeogenomics | -41.08x | 64.12% | $2.13B |
WGSUSGeneDx | -15.74x | 359.59% | $1.67B |
AGLUSagilon health | -6.49x | 92.48% | $1.51B |
INNVUSInnovage | -513.64x | 2,301.70% | $1.30B |
OPKUSOpko Health | -16.69x | 25.99% | $1.22B |
LMRIUSLumexa Imaging | -40.40x | 145.51% | $1.12B |
CSTLUSCastle Biosciences | -52.05x | 51.54% | $1.01B |
AONCUSAmerican Oncology Network | -- | -- | $745.84M |
GMRSUSGMR Solutions | -7.66x | 91.45% | $579.65M |
FLGTUSFulgent Genetics | -6.55x | 42.64% | $553.06M |
PREUSPrenetics Global | -6.33x | 15.02% | $297.44M |
BDSXUSBiodesix | -8.05x | 42.77% | $223.47M |
GAMGUSGlobal Asset Management Group, Inc. | -382.84x | -- | $216.09M |
NAKAUSNakamoto | -0.31x | 102.50% | $131.71M |
CORBFUSGlobal Cord Blood Corporation | -- | -- | $127.35M |
PARKUSPark Dental Partners | -26.70x | -- | $94.39M |
AIRSUSAirSculpt Tech | -7.37x | 33.33% | $86.51M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
